Kodiak Sciences Inc (KOD)
Follow-up data for Kodiaks KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical